CoChat
Sign Up
Cited by 187Chronic Kidney Disease and DiabetesAcute Kidney Injury ResearchRenal Diseases and Glomerulopathies

Rationale and design of the Kidney Precision Medicine Project

Open access
de Boer, Ian H., Alpers, Charles E., Azeloglu, Evren U., Balis, Ulysses G.J., Barasch, Jonathan M., Barisoni, Laura, Blank, Kristina N., Bomback, Andrew S. +190 more·2021·Kidney International
DOI 10.1016/j.kint.2020.08.039PMC PMC8330551
Open this paper in CoChat — free account

Abstract

Chronic kidney disease (CKD) and acute kidney injury (AKI) are common, heterogeneous, and morbid diseases. Mechanistic characterization of CKD and AKI in patients may facilitate a precision-medicine approach to prevention, diagnosis, and treatment. The Kidney Precision Medicine Project aims to ethically and safely obtain kidney biopsies from participants with CKD or AKI, create a reference kidney atlas, and characterize disease subgroups to stratify patients based on molecular features of disease, clinical characteristics, and associated outcomes. An additional aim is to identify critical cells, pathways, and targets for novel therapies and preventive strategies. This project is a multicenter prospective cohort study of adults with CKD or AKI who undergo a protocol kidney biopsy for research purposes. This investigation focuses on kidney diseases that are most prevalent and therefore substantially burden the public health, including CKD attributed to diabetes or hypertension and AKI attributed to ischemic and toxic injuries. Reference kidney tissues (for example, living-donor kidney biopsies) will also be evaluated. Traditional and digital pathology will be combined with transcriptomic, proteomic, and metabolomic analysis of the kidney tissue as well as deep clinical phenotyping for supervised and unsupervised subgroup analysis and systems biology analysis. Participants will be followed prospectively for 10 years to ascertain clinical outcomes. Cell types, locations, and functions will be characterized in health and disease in an open, searchable, online kidney tissue atlas. All data from the Kidney Precision Medicine Project will be made readily available for broad use by scientists, clinicians, and patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.kint.2020.08.039

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In T2D, advanced CKD is a risk factor for hypoglycemia.

    “In T2D, advanced CKD is a risk factor for hypoglycemia (29,79) and, when possible, drugs that control glycemia without increasing risk of hypoglycemia are preferred.”

    From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [29]

    The Introduction discusses CKD in people with diabetes and lists cardiovascular events, infections, and mortality among CKD outcomes, but does not mention hypoglycemia. Searches for hypoglycemia in advanced CKD and for glycemic control found no passage addressing the claimed risk in T2D. The Study design section focuses on relatively early CKD rather than advanced CKD. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 30

  1. [2]Afkarian M, Zelnick LR, Hall YN, Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988–2014. JAMA 2016; 316(6): 602– 10. 27532915 PMC5444809
  2. [3]Al-Jaghbeer M, Dealmeida D, Bilderback A, Ambrosino R, Kellum JA. Clinical Decision Support for In-Hospital AKI. J Am Soc Nephrol 2018; 29(2): 654– 60. 29097621 PMC5791078
  3. [4]Kellum JA, Lameire N, Group KAGW. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013; 17(1): 204. 23394211 PMC4057151
  4. [5]Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 2014; 371(1): 58– 66. 24988558 PMC9720902
  5. [6]Levin A, Tonelli M, Bonventre J, Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 2017; 390(10105): 1888– 917. 28434650
  6. [8]Breyer MD, Susztak K. The next generation of therapeutics for chronic kidney disease. Nature reviews Drug discovery 2016; 15(8): 568– 88. 27230798 PMC5511522
  7. [9]Genovese G, Friedman DJ, Ross MD, Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science (New York, NY 2010; 329(5993): 841– 5. PMC2980843 20647424
  8. [10]Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011; 121(11): 4210– 21. 22045571 PMC3204829
  9. [11]Ralto KM, Rhee EP, Parikh SM. NAD(+) homeostasis in renal health and disease. Nature reviews Nephrology 2020; 16(2): 99– 111. 31673160 PMC7223841
  10. [12]Alpers CE, Hudkins KL. Mouse models of diabetic nephropathy. Current opinion in nephrology and hypertension 2011; 20(3): 278– 84. 21422926 PMC3658822
  11. [13]Brosius FC 3rd, Alpers CE, Bottinger EP, Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009; 20(12): 2503– 12. 19729434 PMC4075053
  12. [14]Bonventre JV, Basile D, Liu KD, AKI: a path forward. Clinical journal of the American Society of Nephrology: CJASN 2013; 8(9): 1606– 8. 23868899 PMC3805072
  13. [15]Breyer MD, Coffman TM, Flessner MF, Diabetic nephropathy: a national dialogue. Clinical journal of the American Society of Nephrology: CJASN 2013; 8(9): 1603– 5. 23788618 PMC3805071
  14. [16]Kaskel F, Batlle D, Beddhu S, Improving CKD therapies and care: a National Dialogue. Clinical journal of the American Society of Nephrology: CJASN 2014; 9(4): 815– 7. 24509296 PMC3974372
  15. [17]Bonventre JV, Boulware LE, Dember LM, The kidney research national dialogue: gearing up to move forward. Clinical journal of the American Society of Nephrology: CJASN 2014; 9(10): 1806– 11. 25225184 PMC4186514
  16. [18]KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 2013; 3(3): 259– 305.
  17. [19]Hall YN, Himmelfarb J. The CKD Classification System in the Precision Medicine Era. Clin J Am Soc Nephrol 2017; 12(2): 346– 8. 27903598 PMC5293342
  18. [20]Lambers Heerspink HJ, Oberbauer R, Perco P, Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. Nephrol Dial Transplant 2015; 30 Suppl 4: iv105– 12. 26209732
  19. [21]Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372(9): 793– 5. 25635347 PMC5101938
  20. [23]Tavassoly I, Goldfarb J, Iyengar R. Systems biology primer: the basic methods and approaches. Essays in biochemistry 2018; 62(4): 487– 500. 30287586
  21. [24]Mulder S, Hamidi H, Kretzler M, Ju W. An integrative systems biology approach for precision medicine in diabetic kidney disease. Diabetes, obesity & metabolism 2018; 20 Suppl 3: 6– 13. PMC6541014 30294956
  22. [25]Kimmel PL, Jefferson N, Norton JM, Star RA. How Community Engagement Is Enhancing NIDDK Research. Clin J Am Soc Nephrol 2019; 14(5): 768– 70. 30917992 PMC6500937
  23. [26]Perazella MA, Coca SG, Hall IE, Iyanam U, Koraishy M, Parikh CR. Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol 2010; 5(3): 402– 8. 20089493 PMC2827582
  24. [27]Corapi KM, Chen JL, Balk EM, Gordon CE. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis 2012; 60(1): 62– 73. 22537423
  25. [28]Moledina DG, Luciano RL, Kukova L, Kidney Biopsy-Related Complications in Hospitalized Patients with Acute Kidney Disease. Clinical journal of the American Society of Nephrology: CJASN 2018; 13(11): 1633– 40. 30348813 PMC6237071
  26. [29]Poggio ED, McClelland RL, Blank K, Systematic Review and Meta-analysis of Native Kidney Biopsy Complications. CJASN [in press] 2020. PMC7646247 33060160
  27. [30]Lake BB, Chen S, Hoshi M, A single-nucleus RNA-sequencing pipeline to decipher the molecular anatomy and pathophysiology of human kidneys. Nat Commun 2019; 10(1): 2832. 31249312 PMC6597610
  28. [31]Menon R, Otto EA, Hoover P, Single cell transcriptomics identifies focal segmental glomerulosclerosis remission endothelial biomarker. JCI insight 2020; 5(6). PMC7213795 32107344
  29. [32]Kohler S, Vasilevsky NA, Engelstad M, The Human Phenotype Ontology in 2017. Nucleic acids research 2017; 45(D1): D865– D76. 27899602 PMC5210535
  30. [33]Heerspink HJL, Perkovic V. Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform. Clin J Am Soc Nephrol 2018; 13(6): 946– 8. 29700075 PMC5989668

Cited by

Sorted by citations

Authors
de Boer, I. H., Alpers, C. E., Azeloglu, E. U., Balis, U. G. J., Barasch, J. M., Barisoni, L., Blank, K. N., Bomback, A. S., Brown, K., Dagher, P. C., Dighe, A. L., Eadon, M. T., El-Achkar, T. M., Gaut, J. P., Hacohen, N., He, Y., Hodgin, J. B., Jain, S., Kellum, J. A., Kiryluk, K., Knight, R., Laszik, Z. G., Lienczewski, C., Mariani, L. H., McClelland, R. L., Menez, S., Moledina, D. G., Mooney, S. D., O’Toole, J. F., Palevsky, P. M., Parikh, C. R., Poggio, E. D., Rosas, S. E., Rosengart, M. R., Sarwal, M. M., Schaub, J. A., Sedor, J. R., Sharma, K., Steck, B., Toto, R. D., Troyanskaya, O. G., Tuttle, K. R., Vazquez, M. A., Waikar, S. S., Williams, K., Wilson, F. P., Zhang, K., Iyengar, R., Kretzler, M., Himmelfarb, J., Knight, R., Lecker, S., Stillman, I., Waikar, S., Mcmahon, G., Weins, A., Short, S., Hacohen, N., Hoover, P., Aulisio, M., Cooperman, L., Herlitz, L., O’Toole, J., Poggio, E., Sedor, J., Jolly, S., Appelbaum, P., Balderes, O., Barasch, J., Bomback, A., Canetta, P. A., d’Agati, V. D., Kiryluk, K., Kudose, S., Mehl, K., Radhakrishnan, J., Weng, C., Barisoni, L., Alexandrov, T., Ashkar, T., Barwinska, D., Dagher, P., Dunn, K., Eadon, M., Ferkowicz, M., Kelly, K., Sutton, T., Winfree, S., Menez, S., Parikh, C., Rosenberg, A., Villalobos, P., Malik, R., Fine, D., Atta, M., Monroy Trujillo, J. M., Slack, A., Rosas, S., Williams, M., Azeloglu, E., He, C. (., Iyengar, R., Hansen, J., Parikh, S., Rovin, B., Anderton, C., Pasa-Tolic, L., Velickovic, D., Lukowski, J., Oliver, G. (., Ardayfio, J., Bebiak, J., Brown, K., Campbell, T., Campbell, C., Hayashi, L., Jefferson, N., Koewler, R., Roberts, G., Saul, J., Shpigel, A., Stutzke, E. C., Wright, L., Miegs, L., Pinkeney, R., Sealfon, R., Troyanskaya, O., Tuttle, K., Dobi, D., Goltsev, Y., Lake, B., Zhang, K., Joanes, M., Laszik, Z., Schroeder, A., Sarwal, M., Sigdel, T., Balis, U., Blanc, V., He, O., Hodgin, J., Kretzler, M., Mariani, L., Menon, R., Otto, E., Schaub, J., Steck, B., Lienczewski, C., Eddy, S., Elder, M., Hall, D., Kellum, J., Kruth, M., Murugan, R., Palevsky, P., Randhawa, P., Rosengart, M., Sims-Lucas, S., Stefanick, M., Stull, S., Tublin, M., Alpers, C., de Boer, I., Dighe, A., Himmelfarb, J., Mcclelland, R., Mooney, S., Shankland, S., Williams, K., Blank, K., Carson, J., Dowd, F., Drager, Z., Park, C., Sharma, K., Zhang, G., Bansal, S., Venkatachalam, M., Kermani, A., Lee, S., Lu, C., Miller, T., Moe, O., Park, H., Sambandam, K., Sanchez, F., Torrealba, J., Robert, T., Vazquez, M., Wang, N., Gaut, J., Jain, S., Vijayan, A., Luciano, R., Moledina, D., Ugochukwu, U., Wilson, F. P., & Alfano, S.
Affiliations
  • Columbia University (US)
  • University of Washington (US)
  • Washington University in St. Louis (US)
  • University of Michigan (US)
  • University of Pittsburgh (US)
  • Yale University (US)
  • Cleveland Clinic (US)
  • Johns Hopkins University (US)
  • Joslin Diabetes Center (US)
  • The University of Texas Southwestern Medical Center (US)
  • Boston University (US)
  • Broad Institute (US)
  • Duke University (US)
  • Indiana University Indianapolis (US)
  • Princeton University (US)
  • University of California San Diego (US)
  • The University of Texas at San Antonio Health Science Center (US)
ORCID
Venue
Kidney International
Publisher
Elsevier BV
Published
2021-03
Volume
99
Issue
3
Pages
498-510
ISSN
0085-2538 (ISSN-L)
DOI
10.1016/j.kint.2020.08.039
PMC
PMC8330551
OpenAlex
W3131249490
Cited by
187
References
1
Citations by year
2026: 32 · 2025: 41 · 2024: 25 · 2023: 31 · 2022: 40 · 2021: 17 · 2020: 1
FWCI
22.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Kidney International (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
Funders
NIDDK
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
Keywords
Kidney Precision Medicine Project, chronic kidney disease, acute kidney injury, renal biopsy, disease subgroups, precision medicine, digital pathology, transcriptomics, proteomics, metabolomics, systems biology, ischemic acute kidney injury, clinical outcomes
MeSH terms
Adult, Humans, Kidney, Prospective Studies, Multicenter Studies as Topic, Proteomics, Renal Insufficiency, Chronic, Precision Medicine, Acute Kidney Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review